Article: FDA issues alert for DDAVP nasal spray, usage could cause seizures.(Warnings)(Brief article)

FDA has requested manufacturers update the prescribing information for desmopressin, marketed as DDAVP Nasal Spray, to include important new information about severe hyponatremia and seizures, the agency stated in a release Dec. 4.

Certain patients taking desmopressin are at risk for developing severe hyponatremia that can result in seizures and death. Children treated with desmopressin intranasal formulations for primary nocturnal enuresis (PNE) are particularly susceptible to severe hyponatremia and seizures.

As such, desmopressin intranasal formulations are ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!